A Multicenter, open-label, uncontrolled, 52-week long-term study in patients with secondary hyperparathyroidism on hemodialysis (ONO-5163-04)
Latest Information Update: 01 Jul 2022
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 22 Nov 2018 Results post-hoc analysis (190) published in the Clinical Therapeutics.
- 15 Jul 2016 Status changed from active, no longer recruiting to completed.
- 16 Jun 2016 New trial record